Baillie Gifford Reduces Moderna Stake by 37.2%
Baillie Gifford Reduces Moderna Stake by 37.2%
I'll start by finding the recent reports and the SEC filings behind them, and pull a current MRNA quote alongside.
Bottom line: The SEC filings show Baillie Gifford cut its reported Moderna stake by 37.2% in Q3 2026, from 18.2M to 11.4M shares. Nothing in the filings points to company-specific distress. The sales came while the stock rose about 175% and while Moderna released positive trial data. The pattern looks more like portfolio-level or valuation-driven trimming. The filings cannot prove intent, and I could not verify the sale dates or prices.
Scale (SEC filings)
- June 30, 2026: Schedule 13G/A filed July 24, 2026 reports , or of the company. The matching 13F-HR (filed Aug 6) ties to the same share count.
- September 30, 2026: The 13F-HR filed November 9, 2026 reports and a reported value of . Dividing value by shares gives per share (formula: value ÷ shares), which matches the Sept. 30 close, so the 13F values the position at quarter-end prices.
- Net reduction: (formula: June shares − September shares), or (formula: (Sept − June) ÷ June).
- Approximate ownership now: About of current shares outstanding (formula: Sept shares ÷ 404,620,975 current shares). This uses today's share count, so treat it as approximate.
Timing
- A 13F is a quarter-end snapshot. It does not show trade dates or execution prices. The reduction happened sometime between July 1 and September 30. The September figure is the first disclosure of it, released about six weeks after quarter-end.
- Shares were sold into a sharp rally. MRNA closed at on June 30 (dividend-adjusted) and at $192.57 on September 30. That is a move (formula: (Sept − June) ÷ June).
- The shares no longer reported were worth about at the September 30 close. This is a scenario, not actual proceeds.
- The stock closed at on November 11, 2026, up since September 30 (formula: (Nov 11 − Sept 30) ÷ Sept 30). Any sales after September 30 will not appear until a later 13F.
Company-specific concern or rebalancing?
Evidence that the sales were not driven by company-specific concern:
- Positive trial data during the window. On August 19, 2026, the Phase 3 melanoma data for the Moderna–Merck personalized cancer vaccine met its primary endpoint. CNBC reported Moderna shares rose about 177% that day.
- Strong results shortly after quarter-end. On November 6, Moderna raised its 2026 revenue growth guidance to 15–25% from up to 10%. This came after the quarter ended, so it did not drive the September sales, but it contradicts any idea of a fundamental deterioration.
- Broad-based trimming. In the captured portion of Baillie's 13F information tables, holdings present in both quarters had lower share counts (formula: decreased ÷ common holdings, ). The table capture was partial and this is a sample, not the full book, but it suggests a portfolio-wide pattern rather than a Moderna-only exit.
Evidence that limits the conclusion:
- The filings do not state reasons. A cut of this size could reflect position sizing after a large gain, valuation, client flows, or a view on the company. The filings cannot distinguish these.
- Analysts quoted by CNBC said Moderna's valuation already reflected expectations for the cancer vaccine before the August data. A trim after a 175% move is consistent with valuation discipline. That is not evidence of a negative company view.
- Silvia News describes the September 2026 position as the smallest since September 2020. I did not check every prior 13F, so I have not verified that claim. The "continued selling" framing in the press is secondary.
- I did not verify whether Baillie filed a final Schedule 13G/A after its stake fell below 5%.
Conclusion: The filings show a large, quarter-long reduction in Baillie's Moderna position. The timing and price data point toward profit-taking or portfolio trimming during a rally, not a reaction to negative company news. The evidence supports "not company-specific distress," but it does not establish the reason for the sales.
Data as of: MRNA price data through the November 11, 2026 close (US Eastern). Holdings data as of September 30, 2026 (13F filed November 9, 2026). Ownership percentage as of June 30, 2026 (13G/A filed July 24, 2026).
Sources
- SEC EDGAR, Schedule 13G/A, Moderna, Inc. filed by Baillie Gifford & Co, filed July 24, 2026 (accession 0001088875-26-000046)
- SEC EDGAR, Form 13F-HR, Baillie Gifford & Co, period June 30, 2026, filed August 6, 2026 (accession 0001088875-26-000057)
- SEC EDGAR, Form 13F-HR, Baillie Gifford & Co, period September 30, 2026, filed November 9, 2026 (accession 0001088875-26-000074)
- Driven Market Data: MRNA quote (November 11, 2026 close, NASDAQ) and daily dividend-adjusted price history, June 1 to November 11, 2026
- CNBC, "Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar," August 19, 2026
- CNBC, "Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction," November 6, 2026
- Silvia News, "Baillie Gifford cuts Moderna stake 37.2% to fewest shares since 2020," November 10, 2026 (secondary; used only for the historical-low comparison)